Home >> Top News >> Therascreen EGFR RGQ PCR kit approved as CDx

Therascreen EGFR RGQ PCR kit approved as CDx

Print Friendly, PDF & Email

Oct. 1, 2018Qiagen announced that the FDA has approved a PMA supplement expanding the labeling claim of the Therascreen EGFR RGQ PCR Kit to allow its use as a companion diagnostic with Pfizer’s Vizimpro (dacomitinib) for first-line treatment of patients with non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or an exon 21 L858R mutation.

“The FDA’s expanded approval of the Therascreen EGFR kit, which was used in the pivotal clinical trial for Vizimpro, will enable physicians to identify patients who may benefit from this medicine,” Mace Rothenberg, MD, chief development officer, oncology, Pfizer global product development, said in a press release.

The Therascreen EGFR RGQ PCR kit is approved as a companion diagnostic to guide the use of three FDA-approved therapies, including Gilotrif (afatinib) from Boehringer Ingelheim and Iressa (gefitinib) from AstraZeneca.

x

Check Also

Qiagen partners with DiaSorin, NeuMoDx

November 2018—Qiagen has introduced an automated, CE-marked workflow for its Quanti-Feron-TB Gold Plus Blood Collection Tubes and a novel DiaSorin Liaison Test on DiaSorin’s Liaison systems. The launch offers Liaison customers high-throughput detection with QFT-Plus as part of the system’s broad menu, and QFT-Plus users will gain an option for full automation of laboratory handling to support TB control efforts. Customers using the new latent TB detection workflow for Liaison systems will purchase the detec-tion components from DiaSorin and the blood collection tube kits from Qiagen. The test is available in Europe and other markets, with an expected U.S. release in 2019 and in China in 2020. In a separate release, Qiagen and NeuMoDx Molecular announced a strategic partnership to commercialize two fully integrated systems for automation of PCR test-ing. Under the agreement, Qiagen will initially distribute the NeuMoDx 288 (for high throughput) and NeuMoDx 96 (for mid-throughput) in Europe and other markets outside of the United States; NeuMoDx will cover the U.S.

X